noscript

News and Announcements

OncoSil Medical CE Mark Update

  • Published October 13, 2015 1:32PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

12th October 2015, ASX Announcement

OnoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to provide the following update on its Conformité Européenne (CE) Mark application for the Company’s OncoSilTM localised radiation treatment for cancer.

As previously advised (ASX announcement, 9 September 2015), OncoSil Medical was granted a Fast Track review by the European regulator to assess its CE Mark application for OcoSilTM in pancreatic and primary liver cancer (HCC).

OncoSil Medical now advises that the Fast Track Face-To-Face review phase has been completed, and it now awaits the final outcome of the review as the Notified Body continues to its assessment over the coming weeks. The Compnay was pleased with the review meeting and anticipates that the Notified Body will make a decision in respect of the CE Mark for OncoSilTM in November.

To read the full announcement, please click here.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now